Changzhou Qianhong Biopharma CO.,LTD manufactures and distributes polysaccharide and protease drugs in China. The company offers heparin sodium, heparin calcium, enoxaparin sodium, dalteparin sodium, nadroparin calcium, pancreatin, heparinoid API, kallidinogenase, and asparaginase, as well as offers berry source and target diet box. It also provides low molecular weight heparin, compound digestive enzyme preparations, and health products. In addition, the company exports its products. The company was founded in 1971 and is headquartered in Changzhou, China.
Research context
Changzhou Qianhong Biopharma CO.,LTD appears in PyInvesting’s Shenzhen Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Changzhou Qianhong Biopharma CO.,LTD is currently in a long term downtrend where the price is trading 2.0% below its 200 day moving average.
From a valuation standpoint, the stock is 70.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.8.
Changzhou Qianhong Biopharma CO.,LTD's total revenue rose by 68.7% to $508M since the same quarter in the previous year.
Its net income has increased by 78.4% to $83M since the same quarter in the previous year.
Finally, its free cash flow grew by 147.8% to $162M since the same quarter in the previous year.
Based on the above factors, Changzhou Qianhong Biopharma CO.,LTD gets an overall score of 4/5.